Towards NanoMedicine Interventions for HIV/AIDS

Lead Research Organisation: University of Liverpool
Department Name: Chemistry

Abstract

Nanomedicines have proven extremely valuable in recent years and many are used daily to treat patients with a range of conditions or needs - from the treatment of cancer and menopausal symptoms to the prevention of organ rejection or malnutrition/weight loss. A range of unmet clinical needs may benefit considerably from the research and application of new nanoparticle synthesis techniques and the development of appropriate nanomedicines and provision of scale-able, commercially viable technologies that can impact patient outcomes is a key goal of nanomedicine research.

Validation of new technologies through optimisation of product performance, demonstration of pharmaceutically relevant manufacturing and in-man pharmacokinetic studies is critical for progression as is the study of nanotoxicology to establish a safety assessment that supports future investment.

To date, a series of candidate nanomedicines for HIV/AIDS treatment have been generated at the University of Liverpool in collaboration with IOTA NanoSolutions Ltd, a specialist start-up company in the UK, and supported by RCUK funding. IOTA is commercialising a novel nanoparticle synthesis technology (initially developed at UoL with EPSRC funding support) that rivals the most successful commercial top-down nanomedicine technology - nanomilling. The HIV/AIDS nanomedicine candidates have been the subject of 3 patent filings and funds are sought to optimise their production and establish their behaviour using clinical research techniques. Additionally the project will seek to dramatically increase the understanding of nanomedicine through fundamental mechanistic studies, thereby producing new insight into the mode of action and the safety of future nanomedicines.

If successful, the programme will produce the first nanomedicine options for HIV/AIDS therapy with benefits for patient care potentially including lower dosing, reduced side effects, better patient-to-patient consistency and a reduction of tablet size. Significant interest has been generated within Medecins Sans Frontiere who are keen to utilise the outputs for charitable medicines in the developing world, treating children with HIV infection with better products and prevent HIV infection in newborns. Currently, to prevent transmission of HIV to children from infected mothers, the World Heath Organisation has recommended dosing from 3 weeks after birth with antiretrovirals. The only children's medicines available include high levels of alcohol to dissolve the poorly water-soluble drugs. The nanomedcines within this programme are dispersible in water and offer a step-forward in paediatric therapy.

The successful establishment of the fundamental research underpinning new nanomedicines will provide a clear advance in the UK's global standing in this emerging area, currently valued at >US$75bn and growing rapidly, with expectations to reach >US$100bn within 3 years.

Planned Impact

The key focus of the proposal is the collaborative progression of research outputs from RCUK Grand Challenge funding to demonstrated nanomedicines with the potential for further development into products and the delivery of improved patient outcomes. Critical to this is the generation of in man PK data as this validates the research by generating relevant evidence of behaviour in man rather than questionable links from animal models to human performance.

The beneficiaries of the research therefore fall into a number of groups including scientists, clinicians, patients and industry. Within the field of nanomaterials and nanomedicine, a series of ongoing societal and governmental debates are discussing the safety and application of nanoscale technologies. The programme will engage fully with this debate and provide insight and new opinion from the direct outputs of the materials, pharmacology and clinical research proposed, with the potential to impact policy decisions.
The charity Médecins Sans Frontière and the Drugs for Neglected Diseases Initiative are highly committed to evaluating the nanomedicine options for the paediatric dosing in the developing world. This holds the possibility of prevention of mother-to-child transmission as the WHO guidelines recommend a prophylactic dosing of antiretrovirals to new-borns as early as 3 weeks old and for up to 8 years. Provision of relevant formulations has been poor and new options are urgently required to prevent transmission during breastfeeding and into the later years. Adoption of the proposed research outputs in sub-Saharan Africa would impact a growing population of HIV patients and help to slow the increasing numbers of infant infections. Within developed countries, HIV nanomedicines may act to increase patient
compliance and reduce patient variability, thereby providing clinicians with therapies with more predictable clinical outcomes and consistency across varying patient populations. Also, it is a fallacy to bieve that HIV is not a concern within the developed world and can be managed as a chronic disease. Infections in teh UK continue to rise alarmingly and maintenance of patient quality of life requires a life-long commitment to a cocktail of drugs with considerable inter-patient variability and side-effects. Although the rate of infection has decreased, the numbers of new infections per year in the UK-alone are still in the thousands and multi-drug resistance (often derived from poor patient compliance) is leaving many patients with fewer therapy options.

If successful, the project will generate therapy options that will be commercially protected and have considerably demonstrated progress towards product manufacture, thereby able to generate future investment. The provision of new data and successful results in this area will show the wide applicability of the nanoparticle synthesis and resulting nanomedicine generation. The project also has the capability to secure the future of a small, high technology company in the North West, building a foundation for considerable investment and commercial revenues. It is also worth noting that outputs from the programme will potentially represent the first nano-antiretroviral commercial therapies after progression to the clinic.
As a platform for future products with a developed supply chain and demonstration of in-man pharmacokinetics, this will generate a significant commercial opportunity for the UK with multiple areas of impact.

Publications

10 25 50

publication icon
Giardiello M Rapid nanoformulation and GMP preparation of antiretroviral drugs for oral HIV nanomedicines and human clinical dosing studies in Converging technology for nanobio-applications of the E-MRS 2014 Spring Meeting

 
Description The formation of candidate nanomedicines for HIV therapy at the bench scale has been translated to clinical manufacturing and received MHRA approval for human testing. Healthy volunteer trials have shown the potential to reduce the oral dose of two of the leading HIV therapies by 50% whilst maintaining drug exposure levels. This is a hugely valuable outcome as it reduces the cost of therapy (estimated at >$500m over 5 years), offers charities the potential to provide therapy for a greater number of patients and reduces pressure on drug manufacturing and supply chains. This represents the world's first orally-dosed nanomedicine candidate for HIV therapy.
Exploitation Route The healthy volunteer trials have formed the basis for translation to generic pharmaceutical scale up and progression through to global charities for distribution to affected populations. A collaboration with the UNITAID funded Medicines Patent Pool has been established (the first academic technology provider to MPP) and development partners have been identified for future scale-up and commercialisation potential. CDAs have been signed and discussions are underway to establish the most efficient way forward.
Sectors Healthcare,Pharmaceuticals and Medical Biotechnology

URL https://www.eurekalert.org/pub_releases/2015-11/uol-npp113015.php
 
Description The outcomes of the research have generated a collaborative agreement with the UNITAID-funded Medicines Patent Pool - the first academic technology provision to MPP. The successful healthy volunteer trial has led to a tendering for industrial development partners and several have signed CDAs to access further information and detailed discussions. Calculations have shown that the potential reduced doses available could save >$500m in the first 5 years of adoption for global charities and offer potential easing of manufacturing pressure for the global supply chain.
First Year Of Impact 2015
Sector Healthcare,Pharmaceuticals and Medical Biotechnology
Impact Types Societal,Economic

 
Description Inclusion of research outputs in PEPFAR watch list for future HIV therapies
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in other policy documents
URL https://www.pepfar.gov/documents/organization/271314.pdf
 
Description Membership of Innovate UK Emerging Technologies and Industries Steering Committee
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Description Industrial Funding
Amount £829,000 (GBP)
Organisation Industry Partners 
Sector Private
Country United States
Start 04/2017 
End 04/2019
 
Description Industrial Funding - Agrochemicals
Amount £572,000 (GBP)
Organisation Industry Partners 
Sector Private
Country United States
Start 01/2016 
End 09/2019
 
Description MRC Funding for Imaging
Amount £914,582 (GBP)
Funding ID MR/K015931/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start  
 
Description NIH Funding from US
Amount £87,922 (GBP)
Organisation National Institutes of Health (NIH) 
Sector Public
Country United States
Start  
 
Description NIH Funding from US
Amount £87,922 (GBP)
Organisation National Institutes of Health (NIH) 
Sector Public
Country United States
Start 10/2013 
End 09/2014
 
Description US NIH R01 funding
Amount $1,210,035 (USD)
Funding ID R01AI114405 
Organisation National Institutes of Health (NIH) 
Sector Public
Country United States
Start  
 
Description USAID PEPFAR ART Simplification
Amount $5,000,000 (USD)
Funding ID AID-OAA-A-15-00069 
Organisation United States Agency for International Development 
Sector Public
Country United States
Start 10/2015 
End 09/2020
 
Description Brazil 
Organisation Federal University of Santa Maria
Country Brazil 
Sector Academic/University 
PI Contribution Hosted a visiting scientist from Departamento de Ciências Farmacêuticas, Universidade Federal de Santa Catarina P.O. Box 476, Florianópolis, SC, 88040-900, Brazil to undertake the evaluation of novel nanomaterials intended for drug delivery strategies. The Liverpool team provided hands on training and direct research relating to in vitro immunological characterisation, in vitro drug disposition assays and physiologically-based pharmacokinetic modelling. The collaboration has resulted in two publications.
Collaborator Contribution Adny Silva spent a period of 8 months at Liverpool learning various assays for pre-clinical assessment of nanomaterials that were generated by her and her colleagues in Departamento de Ciências Farmacêuticas, Universidade Federal de Santa Catarina P.O. Box 476, Florianópolis, SC, 88040-900, Brazil. The Brazilian collaborators therefore generated the materials and helped characterise them in Liverpool. They also co-wrote the two publications.
Impact Silva AH, Locatelli C, Filippin-Monteiro FB, Martin P, Liptrott NJ, Zanetti-Ramos BG, Benetti LC, Nazari EM, Albuquerque CA, Pasa AA, Owen A, Creczynski-Pasa TB. Toxicity and inflammatory response in Swiss albino mice after intraperitoneal and oral administration of polyurethane nanoparticles. Toxicol Lett. 2016 Mar 30;246:17-27. doi: 10.1016/j.toxlet.2016.01.018. Epub 2016 Jan 25.
Start Year 2014
 
Description EU Nanocharacterisation Laboratory 
Organisation University of Glasgow
Department English Language
Country United Kingdom 
Sector Academic/University 
PI Contribution The University of Liverpool team provide critical expertise developed through EPSRC grant funded activity, to the Horizon 2020 funded European Nanocharcterisation Laboratory
Collaborator Contribution Additional input from multiple EU partners to characterise candidate nanomedicines
Impact No outputs as yet
Start Year 2015
 
Description Evaluation of solid drug nanoparticles for pharmaceutical benefits 
Organisation Viiv Healthcare
Country United Kingdom 
Sector Private 
PI Contribution Proprietary APIs studied for nanoscale drug delivery benefits
Collaborator Contribution Provision of proprietary APIs, management of the project and numerous review meetings
Impact Numerous evaluations of novel materials for drug delivery
Start Year 2015
 
Description Medicines Patent Pool 
Organisation Medicines Patent Pool
Country Switzerland 
Sector Private 
PI Contribution Development of prototype and clinical candidate therapies (nanomedicine) for HIV treatment
Collaborator Contribution MPP are seeking partners for scale up and translation of clinical outputs to enable therapy scale up and charitable access
Impact None as yet
Start Year 2015
 
Title CHEMICAL COMPOSITION 
Description A solid composition comprising nanoparticles of atovaquone dispersed within one or more carrier materials, wherein the atovaquone is present in an amount of at least 10 wt%. Also described is an intramuscularly- or subcutaneously-injectable formulation of nanoparticles of atovaquone. 
IP Reference WO2017216564 
Protection Patent application published
Year Protection Granted 2017
Licensed No
Impact First demonstration of antimalarial prophylaxis from long acting depot injection. Impact on research approaches and focus of international charities
 
Title COMPOSITIONS OF EFAVIRENZ 
Description The present inventions relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug efavirenz. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit- E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N-alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV). 
IP Reference WO2013034925 
Protection Patent application published
Year Protection Granted 2013
Licensed Yes
Impact Supporting human clinical trials
 
Title COMPOSITIONS OF EFAVIRENZ 
Description The present inventions relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug efavirenz. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit- E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N-alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV). 
IP Reference WO2013034925 
Protection Patent application published
Year Protection Granted 2013
Licensed No
Impact The patent is supporting a human clinical trial and has initiated interest from global charities and the NIH (US)
 
Title COMPOSITIONS OF LOPINAVIR 
Description The present invention relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug lopinavir. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit- E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N- alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV). 
IP Reference WO2013034926 
Protection Patent application published
Year Protection Granted 2013
Licensed Yes
Impact Currently supporting human clinical trials
 
Title COMPOSITIONS OF LOPINAVIR 
Description The present invention relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug lopinavir. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit- E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N- alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV). 
IP Reference WO2013034926 
Protection Patent application published
Year Protection Granted 2013
Licensed No
Impact This patent is underpinning a human clinical trial and has attracted considerable global interest from charities and NIH (US)
 
Title COMPOSITIONS OF LOPINAVIR AND RITONAVIR 
Description The present inventions relates to a solid compn. and an aq. dispersion comprising nanoparticles of the antiretroviral drugs lopinavir and ritonavir. The solid compn. and aq. dispersion addnl. comprise a mixt. of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol succinate (Vit-E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N-alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol 12-hydroxystearate, polyvinyl alc., and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alc. (PVA), a polyvinyl alc.-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl Me cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for prepg. both the solid compn. and the aq. dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV). 
IP Reference WO2013034927 
Protection Patent application published
Year Protection Granted 2014
Licensed No
Impact Much interest in this patent application as part of a larger portfolio and negotiations to progress to human trials are ongoing
 
Title COMPOSITIONS OF LOPINAVIR AND RITONAVIR 
Description The present inventions relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drugs lopinavir and ritonavir. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol- succinate (Vit-E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N- alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV). 
IP Reference WO2013034927 
Protection Patent application published
Year Protection Granted 2011
Licensed Yes
Impact Currently supporting human clinical trials
 
Title Chemical composition comprising nanoparticles of atovaquone and injectable formulation of atovaquone nanoparticles 
Description A solid compn. comprising nanoparticles of atovaquone dispersed within one or more carrier materials, wherein the atovaquone is present in an amt. of at least 10 wt%. Also described is an i.m.- or s.c.-injectable formulation of nanoparticles of atovaquone. 
IP Reference WO2017216564 
Protection Patent application published
Year Protection Granted 2017
Licensed No
Impact First prophylactic injection demonstration for malaria
 
Title PRODRUG COMPOSITIONS 
Description The present invention provides a composition comprising nanoparticles of prodrugs of certain pharmaceutically active agents, wherein the nanoparticles of prodrugs are dispersed within a carrier material. The present invention further provides processes for the making of the same. 
IP Reference WO2018178722 
Protection Patent application published
Year Protection Granted 2018
Licensed No
Impact Engagement with global pharma companies
 
Title Human trial of candidate nanomedicine for HIV using Efavirenz 
Description Human study of pharmacokinetics of orally dosed nanoparticles of efavirenz aiming at dose and pill burden reduction. Engagement with international charities (Clinton Health Access Initiative; Medicines Patent Pool, MSF) and further funding from NIH (collaboration with Johns Hopkins Medical School) and USAID (Multinational collaboration) to establish potential in other HIV related areas and malarial opportunities. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2016
Development Status Actively seeking support
Clinical Trial? Yes
Impact Awaiting outcomes 
URL https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-004913-41
 
Title Oral Nanomedicine for HIV using Lopinavir 
Description This is an nanomedicine for HIV therapy aiming to dramatically reduce the dose and the overall pill burden for HIV sufferers. There is also potential for paediatric therapy development. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2016
Development Status Actively seeking support
Clinical Trial? Yes
Impact Licence agreement signed with UNITAID-funded Medicines Patent Pool (Geneva) and considerable additional funding to establish potential within other drugs for HIV (USAID multinational collaboration) and malaria (interatction with Johns Hopkins Medical School). In addition, significant engagement with Clinton Health Access Initiative and the securing of an R01 grant from NIH to study long acting HIV nanomedicines with a team from Johns Hopkins Medical School. 
URL https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-004913-41
 
Company Name Tandem Nano Ltd 
Description Tandem Nano Ltd is a nanoformulation company aiming to improve the action, delievry, use and behaviour of poorly soluble compounds 
Year Established 2014 
Impact Currently negotiating meaningful interactions with numerous global companies
Website http://www.tandemnano.com/
 
Description Academic outreach 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Postgraduate students
Results and Impact Research Seminar (invited) to inform audience of Nanomedicine and impact of new therapeutic research
Year(s) Of Engagement Activity 2018
 
Description Colorectal Therapies Healthcare Technologies Co-operative Workshop Nanoparticle-Enhanced Radiotherapy, UCL, London 27th October 2017 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Dissemination and discussion of optimal approaches that may be taken for therapy options for colorectal cancer
Year(s) Of Engagement Activity 2017
 
Description Industrial engagement in ongoing research activities 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Solid drug nanoparticle technology evaluation for industrial uptake
Year(s) Of Engagement Activity 2018,2019
 
Description Meeting to discuss research outputs with Global Charity (Clinton Health Access Initiative) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Third sector organisations
Results and Impact Activity was used to engage with the Clinton Health Access Initiative to receive support and garner interest in translational activities directed at candidate global HIV nanomedicine therapy development
Year(s) Of Engagement Activity 2015
 
Description Meeting with industry (Revolymer) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Industry/Business
Results and Impact Engagement with research activities and future licence/collaborative research opportunities
Year(s) Of Engagement Activity 2015
 
Description Meetings with Medicines Patent Pool (Geneva) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Third sector organisations
Results and Impact Discussions to evaluate licence opportunities to allow translation of research outputs through charitable funding and generic pharma companies. MPP are UNITAID funded
Year(s) Of Engagement Activity 2014,2015
 
Description Pint of Science 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact The international Pint of Science public engagement science festival aiming to communicate contemporary scientific developments to the general public in an interesting, engaging and approachable way by bringing scientists to the pub and other accessible places.
Year(s) Of Engagement Activity 2017
URL https://news.liverpool.ac.uk/2017/04/03/drink-think-pint-science-festival-coming-liverpool/
 
Description Princes Teaching Institute CPD 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Schools
Results and Impact CPD for teachers. Presentation designed to update teachers with up to date information to allow teaching knowledge in Nanomedicine
Year(s) Of Engagement Activity 2014
 
Description Schools Outreach activity 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact Vardean College/RSC Sixth former science meeting. Engagement with 6th formers to explain current progress in Nanomedicine
Year(s) Of Engagement Activity 2016
 
Description University of Liverpool Open House 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Public engagement activity to engage public with UoL research and Nanomedicine
Year(s) Of Engagement Activity 2018
 
Description Website for the British Society for Nanomedicine 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact As part of the creation and launch of the British Society for Nanomedicine as website has been created allowing access to information for children, schools, the public and scientists (academic and industrial)

The Society now has >300 members globally and has held multiple meetings
Year(s) Of Engagement Activity 2012